Testing flashing light glasses for Parkinson's disease symptoms
Tests flashing light glasses in adults with Parkinson's disease, aged 50 to 70.
Plain-language title generated from the registry record
Registry title: A Single-blind, Randomized, Controlled Clinical Study of Flash Stimulation Therapy in Parkinson's Disease
Key facts
- Where
- Hangzhou, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 70 years old?
Source: NCT06848621, who can take part
Where in China
- The Second Affiliated Hospital of Zhejiang University School of MedicineHangzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Trial code
- NCT06848621
- Record updated
- 27 February 2025
- Original description
The aim of this study was to evaluate the effect of flash stimulation therapy on the function of the cerebral glymphatic system and efficacy of improving symptoms in PD patients.Read full original descriptionShow less
A Single-blind, Randomized, Controlled Clinical Study of Flash Stimulation Therapy in Parkinson's Disease
The aim of this study was to evaluate the effect of flash stimulation therapy on the function of the cerebral glymphatic system and efficacy of improving symptoms in PD patients.
Inclusion: PD patients who meet the diagnostic criteria of the International Movement Disorders Association (MDS), between the ages of 50 and 70 years, the course of disease ≤5 years, and the Hoehn \& Yahr stage ≤3; Anti-PD drugs were taken regularly for at least one month before screening, and symptoms were stable; The fixed bedtime in the past month is between 9:00 p.m. and 1:00 a.m., and the total sleep time is ≥6 hours; Have the ability to understand and voluntarily sign informed consent; Have good compliance and are willing to complete all follow-up required by this program.
Exclusion: Alcohol, coffee, or drug abusers in the past 6 months; Used drugs or health products that regulate sleep function or affect sleep within 14 days before enrollment or less than 5 drug half-lives; Taking drugs that may impair cognitive ability, such as anticholinergic drugs, memory enhancing drugs, etc., within 7 days before enrollment; Secondary insomnia: including sleep disorders (restless leg syndrome, periodic limb movement disorder, sleep-related breathing disorders, etc.), physical diseases, mental disorders, psychoactive substance abuse; suffering from photosensitive dermatitis, epilepsy and other diseases that are not suitable for flash stimulation; Mental illness: such as anxiety, depression, schizophrenia and post-traumatic stress disorder caused by insomnia; suffering from other neurodegenerative diseases; the subject is unable to complete the test or follow-up; There are endoplants in the body that cannot be examined by MRI; Inability to lie flat; Other situations in which the researcher considers it inappropriate to participate in the study.